StressMarq Biosciences Inc. and Cellectricon are pleased to announce a collaboration to develop next-generation reagents and assays for neurodegenerative disease research.

StressMarq offers a unique reagent portfolio of pre-formed fibrils of tau, alpha-synuclein and other proteins that can be used to study diseases such as Alzheimer’s and Parkinson’s. Cellectricon is a collaborative services provider dedicated to advancing drug discovery and research in the areas of chronic pain and neurodegenerative disease. They have developed a high capacity microfluidics platform to model the hallmark features of neurodegenerative diseases, including cell-to-cell transmission of neurodegenerative disease associated peptides (NDAPs) in neuronal circuits. The two companies will work together to provide the scientific community with next-generation reagents and assays for neurodegenerative disease research.

Ariel Louwrier, President & CEO of StressMarq Biosciences and Sebastian Illes, Director of CNS research at Cellectricon recently presented a webinar about fibrillar and oligomeric constructs of neurodegenerative disease associated peptides and their utility in disease modelling.

Learn more about StressMarq’s cutting-edge products for neurodegenerative disease research: https://www.stressmarq.com/PFFs and Cellectricon’s Pain and CNS Discovery Services: https://www.cellectricon.com.